首页 > 最新文献

Joint Bone Spine最新文献

英文 中文
Could the anti-modified protein antibody concept help better define seronegative rheumatoid arthritis? 抗修饰蛋白抗体概念能否帮助更好地界定血清阴性类风湿性关节炎?
IF 3.8 3区 医学 Q1 RHEUMATOLOGY Pub Date : 2025-02-25 DOI: 10.1016/j.jbspin.2025.105869
Pauline Brevet, Manuel Fréret, Eric Barat, Thierry Lequerré, Olivier Boyer, Olivier Vittecoq
{"title":"Could the anti-modified protein antibody concept help better define seronegative rheumatoid arthritis?","authors":"Pauline Brevet, Manuel Fréret, Eric Barat, Thierry Lequerré, Olivier Boyer, Olivier Vittecoq","doi":"10.1016/j.jbspin.2025.105869","DOIUrl":"https://doi.org/10.1016/j.jbspin.2025.105869","url":null,"abstract":"","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":" ","pages":"105869"},"PeriodicalIF":3.8,"publicationDate":"2025-02-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143525200","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Frailty during polymyalgia rheumatica, giant cell arteritis and other inflammatory rheumatic diseases.
IF 3.8 3区 医学 Q1 RHEUMATOLOGY Pub Date : 2025-02-24 DOI: 10.1016/j.jbspin.2025.105864
Anne Tournadre

Recent data suggest a pathophysiological role of aging and immuno-senescence during polymyalgia rheumatica (PMR) and giant cell arteritis (GCA), by definition rheumatic disease of the elderly. During aging, there is a decline in major physiological functions (immune system, muscle, cognitive, endocrine, cardiovascular, respiratory and renal functions), which combined with multi-morbidity, environmental factors and polypharmacy can lead to frailty. Frailty is a clinical syndrome and dynamic concept including a pre-frailty stage; it reflects a reduction in physiological reserve capacities which alters the mechanisms of adaptation to stress. It results in the inability of a vulnerable subject to return to baseline homoeostasis after minor stress, increasing the risk of hospitalization, loss of autonomy and death. To date, there are no consensual criteria for frailty and its assessment in clinical practice remains difficult, based either on physical criteria including weight loss, fatigue, reduction in muscular strength and walking, inactivity or on a multidimensional geriatric assessment. The impact on morbidity and mortality and quality of life, the possibility of detecting reversible stages of pre-frailty and of implementing preventive measures justify interest in rheumatology as the number of patients aged 65 years and older with inflammatory rheumatic diseases is increasing. If there are no specific recommendations for the management of frailty or pre-frailty, recommendations for exercises, physical activity and nutrition to limit sarcopenia and comorbidities can be applied. The association with multi-morbidity and its additive effect reinforces the need for screening, prevention and specific management of comorbidities, particularly infections, osteoporosis, cardiovascular diseases, during chronic inflammatory rheumatic diseases, PMR and GCA.

{"title":"Frailty during polymyalgia rheumatica, giant cell arteritis and other inflammatory rheumatic diseases.","authors":"Anne Tournadre","doi":"10.1016/j.jbspin.2025.105864","DOIUrl":"https://doi.org/10.1016/j.jbspin.2025.105864","url":null,"abstract":"<p><p>Recent data suggest a pathophysiological role of aging and immuno-senescence during polymyalgia rheumatica (PMR) and giant cell arteritis (GCA), by definition rheumatic disease of the elderly. During aging, there is a decline in major physiological functions (immune system, muscle, cognitive, endocrine, cardiovascular, respiratory and renal functions), which combined with multi-morbidity, environmental factors and polypharmacy can lead to frailty. Frailty is a clinical syndrome and dynamic concept including a pre-frailty stage; it reflects a reduction in physiological reserve capacities which alters the mechanisms of adaptation to stress. It results in the inability of a vulnerable subject to return to baseline homoeostasis after minor stress, increasing the risk of hospitalization, loss of autonomy and death. To date, there are no consensual criteria for frailty and its assessment in clinical practice remains difficult, based either on physical criteria including weight loss, fatigue, reduction in muscular strength and walking, inactivity or on a multidimensional geriatric assessment. The impact on morbidity and mortality and quality of life, the possibility of detecting reversible stages of pre-frailty and of implementing preventive measures justify interest in rheumatology as the number of patients aged 65 years and older with inflammatory rheumatic diseases is increasing. If there are no specific recommendations for the management of frailty or pre-frailty, recommendations for exercises, physical activity and nutrition to limit sarcopenia and comorbidities can be applied. The association with multi-morbidity and its additive effect reinforces the need for screening, prevention and specific management of comorbidities, particularly infections, osteoporosis, cardiovascular diseases, during chronic inflammatory rheumatic diseases, PMR and GCA.</p>","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":" ","pages":"105864"},"PeriodicalIF":3.8,"publicationDate":"2025-02-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143517300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Giant cell arteritis: role of surgery in the management of vascular complications.
IF 3.8 3区 医学 Q1 RHEUMATOLOGY Pub Date : 2025-02-19 DOI: 10.1016/j.jbspin.2025.105862
Hélène Greigert, Camil-Cassien Bamdé, André Ramon, Eric Steinmetz, Yannick Béjot, Olivier Bouchot, Bernard Bonnotte, Maxime Samson

Apart from life-threatening and/or functional emergencies, treatment of vascular lesions in giant cell arteritis (GCA) is medical. Revascularization may be considered if the lesion remains symptomatic or progressive despite optimal medical treatment, provided that there is no disease-related inflammation, and always managed by a team of trained experts. The main risk associated with aortic involvement (aortitis) is the development of an aneurysm, most often in the thoracic aorta, after several years of progression. Indications and surgical techniques used to manage these aneurysms follow the recommendations for the general population. In peripheral artery disease, lesions are characterized by parietal thickening, stenosis and sometimes occlusion, which can lead to exertional claudication or chronic permanent ischemia. Open or endovascular surgical management of these stenotic lesions is frequently complicated by restenosis. The role of endovascular techniques in the management of inflammatory lesions is debated, but there is a preference for open surgery, particularly in the lower limbs. Cervical and cerebral arteries also present a risk of stenosis leading to stroke. Balloon dilation and/or stenting of cervical or cerebral arteries during GCA carries a high risk of rupture and restenosis, and remains a rescue treatment limited to certain specific cases of stroke where there are concerns about patient prognosis in the absence of intervention.

除危及生命和/或功能性急症外,巨细胞动脉炎(GCA)血管病变的治疗均为药物治疗。如果在接受最佳药物治疗后病变仍无症状或仍在进展,则可考虑进行血管重建,但前提是不存在与疾病相关的炎症,并始终由训练有素的专家团队进行管理。主动脉受累(大动脉炎)的主要风险是经过数年进展后形成动脉瘤,最常见的是胸主动脉。治疗这些动脉瘤的适应症和手术技术与普通人群相同。在外周动脉疾病中,病变的特点是动脉旁增厚、狭窄,有时甚至闭塞,可导致劳累性跛行或慢性永久性缺血。对这些狭窄病变进行开放或血管内手术治疗时,经常会因血管再狭窄而复杂化。血管内技术在炎症病变治疗中的作用还存在争议,但人们更倾向于开放手术,尤其是在下肢。颈动脉和脑动脉也存在狭窄导致中风的风险。在 GCA 期间对颈动脉或脑动脉进行球囊扩张和/或支架植入术具有很高的破裂和再狭窄风险,因此仍然是一种抢救性治疗方法,仅限于某些特定的中风病例,在这些病例中,如果不采取干预措施,患者的预后令人担忧。
{"title":"Giant cell arteritis: role of surgery in the management of vascular complications.","authors":"Hélène Greigert, Camil-Cassien Bamdé, André Ramon, Eric Steinmetz, Yannick Béjot, Olivier Bouchot, Bernard Bonnotte, Maxime Samson","doi":"10.1016/j.jbspin.2025.105862","DOIUrl":"https://doi.org/10.1016/j.jbspin.2025.105862","url":null,"abstract":"<p><p>Apart from life-threatening and/or functional emergencies, treatment of vascular lesions in giant cell arteritis (GCA) is medical. Revascularization may be considered if the lesion remains symptomatic or progressive despite optimal medical treatment, provided that there is no disease-related inflammation, and always managed by a team of trained experts. The main risk associated with aortic involvement (aortitis) is the development of an aneurysm, most often in the thoracic aorta, after several years of progression. Indications and surgical techniques used to manage these aneurysms follow the recommendations for the general population. In peripheral artery disease, lesions are characterized by parietal thickening, stenosis and sometimes occlusion, which can lead to exertional claudication or chronic permanent ischemia. Open or endovascular surgical management of these stenotic lesions is frequently complicated by restenosis. The role of endovascular techniques in the management of inflammatory lesions is debated, but there is a preference for open surgery, particularly in the lower limbs. Cervical and cerebral arteries also present a risk of stenosis leading to stroke. Balloon dilation and/or stenting of cervical or cerebral arteries during GCA carries a high risk of rupture and restenosis, and remains a rescue treatment limited to certain specific cases of stroke where there are concerns about patient prognosis in the absence of intervention.</p>","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":" ","pages":"105862"},"PeriodicalIF":3.8,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143473319","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The role of senescence in polymyalgia rheumatica and giant cell arteritis
IF 3.8 3区 医学 Q1 RHEUMATOLOGY Pub Date : 2025-02-19 DOI: 10.1016/j.jbspin.2025.105860
Guillermo Carvajal Alegria
{"title":"The role of senescence in polymyalgia rheumatica and giant cell arteritis","authors":"Guillermo Carvajal Alegria","doi":"10.1016/j.jbspin.2025.105860","DOIUrl":"10.1016/j.jbspin.2025.105860","url":null,"abstract":"","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":"92 5","pages":"Article 105860"},"PeriodicalIF":3.8,"publicationDate":"2025-02-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143473322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
bDMARD Drug Survival In Combination Therapy With Methotrexate In Psoriatic Arthritis: a Systematic Literature Review And Meta-analysis.
IF 3.8 3区 医学 Q1 RHEUMATOLOGY Pub Date : 2025-02-18 DOI: 10.1016/j.jbspin.2025.105854
Sélina Hanna, Tiphaine Dujardin, Philippe Gaudin, Athan Baillet, Xavier Romand

Background/purpose: Combination therapy with methotrexate (MTX) has shown to improve biologic Disease Modifying Rheumatic Drugs (bDMARD) survival in rheumatoid arthritis, but interest in MTX combination therapy in Psoriatic Arthritis (PsA) remains controversial. We conducted a systematic literature review and meta-analysis to study whether a combination therapy bDMARD and MTX improves bDMARD drug survival in PsA.

Methods: We performed a systematic literature review to identify all pertinent articles studying ts/bDMARDs drugs survival (TNF inhibitors (TNFi), IL-17, IL-23, IL-12/23 and JAK inhibitors) and MTX in PsA up until December 2023. Hazard ratio's (HR) were extracted. A random-effect model and inverse-variance method were used. Sensitivity and subgroup analyses were performed to identify sources of heterogeneity and to confirm the robustness of the results.

Results: 2,299 records were identified, and twenty studies were included, with a total of 30,634 patients with PsA. All studies were observational. Two studies involved bDMARDs other than TNFi. Combination therapy with MTX was found to be associated with a superior bDMARDs drug survival (HR = 0.82 [CI95%, 0.75, 0.89], p-value < 0.001, I2=45%) and TNFi drug survival (HR=0.79 [CI95%, 0.73, 0.86], p-value < 0.001, I2=27%). A meta-analysis for non-TNFi was not possible due to the limited number of publications.

Conclusion: This meta-analysis shows the positive association between combination therapy bDMARD with MTX and a better bDMARDs drug survival, especially with TNFi. Further studies are needed to confirm this hypothesis with robust evidence such as randomised controlled trials.

背景/目的:与甲氨蝶呤(MTX)的联合疗法已被证明可改善类风湿性关节炎中生物改变病情药物(bDMARD)的存活率,但对银屑病关节炎(PsA)中MTX联合疗法的兴趣仍存在争议。我们进行了一项系统性文献综述和荟萃分析,研究 bDMARD 和 MTX 联合疗法是否能提高 bDMARD 药物在 PsA 中的存活率:我们进行了系统性文献综述,以确定截至2023年12月所有研究ts/bDMARDs药物(TNF抑制剂(TNFi)、IL-17、IL-23、IL-12/23和JAK抑制剂)和MTX在PsA中存活率的相关文章。提取了危险比(HR)。采用随机效应模型和逆方差法。进行了敏感性分析和亚组分析,以确定异质性的来源,并确认结果的稳健性。结果:共发现 2,299 条记录,纳入了 20 项研究,共计 30,634 名 PsA 患者。所有研究均为观察性研究。两项研究涉及 TNFi 之外的 bDMARDs。研究发现,与MTX联合治疗可提高bDMARDs药物的生存率(HR=0.82 [CI95%,0.75,0.89],P值<0.001,I2=45%)和TNFi药物的生存率(HR=0.79 [CI95%,0.73,0.86],P值<0.001,I2=27%)。由于论文数量有限,无法对非TNFi进行荟萃分析:这项荟萃分析表明,bDMARD与MTX联合治疗与bDMARDs药物生存率之间存在正相关,尤其是TNFi。还需要进一步研究,通过随机对照试验等有力证据来证实这一假设。
{"title":"bDMARD Drug Survival In Combination Therapy With Methotrexate In Psoriatic Arthritis: a Systematic Literature Review And Meta-analysis.","authors":"Sélina Hanna, Tiphaine Dujardin, Philippe Gaudin, Athan Baillet, Xavier Romand","doi":"10.1016/j.jbspin.2025.105854","DOIUrl":"https://doi.org/10.1016/j.jbspin.2025.105854","url":null,"abstract":"<p><strong>Background/purpose: </strong>Combination therapy with methotrexate (MTX) has shown to improve biologic Disease Modifying Rheumatic Drugs (bDMARD) survival in rheumatoid arthritis, but interest in MTX combination therapy in Psoriatic Arthritis (PsA) remains controversial. We conducted a systematic literature review and meta-analysis to study whether a combination therapy bDMARD and MTX improves bDMARD drug survival in PsA.</p><p><strong>Methods: </strong>We performed a systematic literature review to identify all pertinent articles studying ts/bDMARDs drugs survival (TNF inhibitors (TNFi), IL-17, IL-23, IL-12/23 and JAK inhibitors) and MTX in PsA up until December 2023. Hazard ratio's (HR) were extracted. A random-effect model and inverse-variance method were used. Sensitivity and subgroup analyses were performed to identify sources of heterogeneity and to confirm the robustness of the results.</p><p><strong>Results: </strong>2,299 records were identified, and twenty studies were included, with a total of 30,634 patients with PsA. All studies were observational. Two studies involved bDMARDs other than TNFi. Combination therapy with MTX was found to be associated with a superior bDMARDs drug survival (HR = 0.82 [CI95%, 0.75, 0.89], p-value < 0.001, I<sup>2</sup>=45%) and TNFi drug survival (HR=0.79 [CI95%, 0.73, 0.86], p-value < 0.001, I<sup>2</sup>=27%). A meta-analysis for non-TNFi was not possible due to the limited number of publications.</p><p><strong>Conclusion: </strong>This meta-analysis shows the positive association between combination therapy bDMARD with MTX and a better bDMARDs drug survival, especially with TNFi. Further studies are needed to confirm this hypothesis with robust evidence such as randomised controlled trials.</p>","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":" ","pages":"105854"},"PeriodicalIF":3.8,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143469937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Answer to Dou et al. and to Chen et al.
IF 3.8 3区 医学 Q1 RHEUMATOLOGY Pub Date : 2025-02-18 DOI: 10.1016/j.jbspin.2025.105856
Anling Luo, Qin Yang, Zhao Zhang, Yujia Yang, Xuzi Li, Yiting Deng, Li He, Muke Zhou
{"title":"Answer to Dou et al. and to Chen et al.","authors":"Anling Luo,&nbsp;Qin Yang,&nbsp;Zhao Zhang,&nbsp;Yujia Yang,&nbsp;Xuzi Li,&nbsp;Yiting Deng,&nbsp;Li He,&nbsp;Muke Zhou","doi":"10.1016/j.jbspin.2025.105856","DOIUrl":"10.1016/j.jbspin.2025.105856","url":null,"abstract":"","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":"92 3","pages":"Article 105856"},"PeriodicalIF":3.8,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143469934","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comment on: “Association between ankylosing spondylitis and neurodegenerative diseases: Systematic review and meta-analysis” by Luo et al. Joint Bone Spine 2024:105793
IF 3.8 3区 医学 Q1 RHEUMATOLOGY Pub Date : 2025-02-18 DOI: 10.1016/j.jbspin.2025.105857
Jinxiang Peng , Jinmei Tan , Haozhu Chen
{"title":"Comment on: “Association between ankylosing spondylitis and neurodegenerative diseases: Systematic review and meta-analysis” by Luo et al. Joint Bone Spine 2024:105793","authors":"Jinxiang Peng ,&nbsp;Jinmei Tan ,&nbsp;Haozhu Chen","doi":"10.1016/j.jbspin.2025.105857","DOIUrl":"10.1016/j.jbspin.2025.105857","url":null,"abstract":"","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":"92 3","pages":"Article 105857"},"PeriodicalIF":3.8,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143469997","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Exploring the Link Between Ankylosing Spondylitis and Neurodegenerative Diseases: Insights from Mendelian Randomization. Comment on: "Association between ankylosing spondylitis and neurodegenerative diseases: systematic review and meta-analysis" by Luo et al. Joint Bone Spine 2024:105793.
IF 3.8 3区 医学 Q1 RHEUMATOLOGY Pub Date : 2025-02-18 DOI: 10.1016/j.jbspin.2025.105859
Shulin Dou, Wei Fang, Wei Wang, Hailiang Wang
{"title":"Exploring the Link Between Ankylosing Spondylitis and Neurodegenerative Diseases: Insights from Mendelian Randomization. Comment on: \"Association between ankylosing spondylitis and neurodegenerative diseases: systematic review and meta-analysis\" by Luo et al. Joint Bone Spine 2024:105793.","authors":"Shulin Dou, Wei Fang, Wei Wang, Hailiang Wang","doi":"10.1016/j.jbspin.2025.105859","DOIUrl":"https://doi.org/10.1016/j.jbspin.2025.105859","url":null,"abstract":"","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":" ","pages":"105859"},"PeriodicalIF":3.8,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143470017","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Daily or intermittent vitamin D supplementation in patients with or at risk of osteoporosis: Position statement from the GRIO
IF 3.8 3区 医学 Q1 RHEUMATOLOGY Pub Date : 2025-02-18 DOI: 10.1016/j.jbspin.2025.105858
Marie-Eva Pickering , Jean-Claude Souberbielle , Anne Boutten , Véronique Breuil , Karine Briot , Roland Chapurlat , Patrice Fardellone , Rose-Marie Javier , Eugénie Koumakis , Bernard Cortet , Groupe de Recherche et d’Information sur les Ostéoporoses (GRIO)
Advantages and disadvantages of intermittent versus daily vitamin D supplementation especially in adults with or at risk of osteoporosis are discussed by the Osteoporosis Research and Information Group (GRIO). The analysis of the literature suggests that intermittent long-term high doses vitamin D supplementation (such as 60,000 IU/month or more), may increase the risk of falls, fracture and premature death in certain populations, while daily doses of 800–1000 IU with calcium decrease falls and non-vertebral fractures in the elderly with vitamin D deficiency. In patients with or at risk of osteoporosis we hence recommend measuring the 25(OH)D concentration prior to supplementation and to provide vitamin D supplementation (with optimization of calcium intake if needed) to obtain a concentration between 30 and 60 ng/mL. We recommend the use of an initial loading dose, especially in those who need a quick repletion of vitamin D store (symptoms of osteomalacia and/or 25(OH)D concentration < 12 ng/mL, patients eligible for treatment with potent antiresorptive therapy), followed by a maintenance dose. A daily supplementation should be the rule when possible. When daily forms are however not available or not reimbursed, we recommend, like other experts, to continue using intermittent dosing with the smallest available dose (≤ 50,000 IU) and the shortest interval between doses as a stopgap until reimbursement or adequate daily pharmaceutical forms (pills or soft capsules of 1000, 2000 IU) are available.
骨质疏松症研究与信息组(GRIO)讨论了间歇性补充维生素 D 与每日补充维生素 D 的利弊,尤其是对患有骨质疏松症或有骨质疏松症风险的成年人而言。文献分析表明,间歇性长期大剂量补充维生素 D(如每月 60,000 IU 或更多)可能会增加某些人群跌倒、骨折和过早死亡的风险,而每日 800-1000 IU 剂量的维生素 D 和钙可减少维生素 D 缺乏症老人跌倒和非椎体骨折的风险。因此,对于骨质疏松症患者或有骨质疏松症风险的患者,我们建议在补充维生素 D 之前测量 25(OH)D 浓度,并补充维生素 D(必要时优化钙摄入量),以获得 30 至 60 纳克/毫升的浓度。我们建议使用初始负荷剂量,尤其是对于那些需要快速补充维生素 D 的人群(骨软化症状和/或 25(OH)D 浓度在 30 至 60 纳克/毫升之间)。
{"title":"Daily or intermittent vitamin D supplementation in patients with or at risk of osteoporosis: Position statement from the GRIO","authors":"Marie-Eva Pickering ,&nbsp;Jean-Claude Souberbielle ,&nbsp;Anne Boutten ,&nbsp;Véronique Breuil ,&nbsp;Karine Briot ,&nbsp;Roland Chapurlat ,&nbsp;Patrice Fardellone ,&nbsp;Rose-Marie Javier ,&nbsp;Eugénie Koumakis ,&nbsp;Bernard Cortet ,&nbsp;Groupe de Recherche et d’Information sur les Ostéoporoses (GRIO)","doi":"10.1016/j.jbspin.2025.105858","DOIUrl":"10.1016/j.jbspin.2025.105858","url":null,"abstract":"<div><div>Advantages and disadvantages of intermittent versus daily vitamin D supplementation especially in adults with or at risk of osteoporosis are discussed by the Osteoporosis Research and Information Group (GRIO). The analysis of the literature suggests that intermittent long-term high doses vitamin D supplementation (such as 60,000<!--> <!-->IU/month or more), may increase the risk of falls, fracture and premature death in certain populations, while daily doses of 800–1000<!--> <!-->IU with calcium decrease falls and non-vertebral fractures in the elderly with vitamin D deficiency. In patients with or at risk of osteoporosis we hence recommend measuring the 25(OH)D concentration prior to supplementation and to provide vitamin D supplementation (with optimization of calcium intake if needed) to obtain a concentration between 30 and 60<!--> <!-->ng/mL. We recommend the use of an initial loading dose, especially in those who need a quick repletion of vitamin D store (symptoms of osteomalacia and/or 25(OH)D concentration &lt;<!--> <!-->12<!--> <!-->ng/mL, patients eligible for treatment with potent antiresorptive therapy), followed by a maintenance dose. A daily supplementation should be the rule when possible. When daily forms are however not available or not reimbursed, we recommend, like other experts, to continue using intermittent dosing with the smallest available dose (≤<!--> <!-->50,000<!--> <!-->IU) and the shortest interval between doses as a stopgap until reimbursement or adequate daily pharmaceutical forms (pills or soft capsules of 1000, 2000<!--> <!-->IU) are available.</div></div>","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":"92 3","pages":"Article 105858"},"PeriodicalIF":3.8,"publicationDate":"2025-02-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143470002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Bilateral parotitis revealing giant cell arteritis: A case report
IF 3.8 3区 医学 Q1 RHEUMATOLOGY Pub Date : 2025-02-13 DOI: 10.1016/j.jbspin.2025.105855
Robin Arcani , Tatiana Horowitz , Pierre-André Jarrot , Myriam Debelle , Patrick Villani , Aurélie Daumas
We report the atypical case of giant cell arteritis (GCA) in an 88-year-old woman, whose primary symptom was parotitis. The patient presented with a three-week history of painful bilateral parotid enlargement and mild undated morning headaches that were relieved with acetaminophen, but she did not have classic GCA symptoms such as jaw claudication or scalp tenderness. Biological tests revealed biological inflammation. Parotid glands did not show any structural abnormalities. A Doppler ultrasound of the temporal arteries showed inflammation, and a positron emission tomography/computed tomography scan confirmed hypermetabolism in multiple arteries, including those supplying the parotid glands. Temporal artery biopsy confirmed GCA. The patient was treated with prednisone, leading to a rapid improvement in symptoms and inflammatory markers. This case highlights a rare presentation of GCA, where parotitis is the main symptom. GCA should be considered in elderly patients with persistent inflammation and parotitis, particularly when other common causes are ruled out.
{"title":"Bilateral parotitis revealing giant cell arteritis: A case report","authors":"Robin Arcani ,&nbsp;Tatiana Horowitz ,&nbsp;Pierre-André Jarrot ,&nbsp;Myriam Debelle ,&nbsp;Patrick Villani ,&nbsp;Aurélie Daumas","doi":"10.1016/j.jbspin.2025.105855","DOIUrl":"10.1016/j.jbspin.2025.105855","url":null,"abstract":"<div><div>We report the atypical case of giant cell arteritis (GCA) in an 88-year-old woman, whose primary symptom was parotitis. The patient presented with a three-week history of painful bilateral parotid enlargement and mild undated morning headaches that were relieved with acetaminophen, but she did not have classic GCA symptoms such as jaw claudication or scalp tenderness. Biological tests revealed biological inflammation. Parotid glands did not show any structural abnormalities. A Doppler ultrasound of the temporal arteries showed inflammation, and a positron emission tomography/computed tomography scan confirmed hypermetabolism in multiple arteries, including those supplying the parotid glands. Temporal artery biopsy confirmed GCA. The patient was treated with prednisone, leading to a rapid improvement in symptoms and inflammatory markers. This case highlights a rare presentation of GCA, where parotitis is the main symptom. GCA should be considered in elderly patients with persistent inflammation and parotitis, particularly when other common causes are ruled out.</div></div>","PeriodicalId":54902,"journal":{"name":"Joint Bone Spine","volume":"92 3","pages":"Article 105855"},"PeriodicalIF":3.8,"publicationDate":"2025-02-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143426831","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Joint Bone Spine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1